Medistim's Record Quarter Is a Price-and-Mix Story, Not a Volume One

A record, with an asterisk

Medistim ASA does not often produce a quarter like this. Revenue of NOK 210 million, up 25.9% reported and 31.5% in constant currency; own-product sales up 34.6% currency-neutral; EBIT of NOK 63.1 million at a 30.1% margin; gross margin expanding from 81.5% to 84.5%. Americas grew 51.7% in constant currency to NOK 116.9 million, Asia Pacific 44.6% to NOK 33.6 million with China up 59.5%, and EMEA 5.5%. Year-to-date revenue crossed NOK 600 million for the first time at NOK 613.7 million.

But the mechanism behind the growth matters more than the growth itself. This was not a quarter of surging utilisation. It was a quarter of product mix and price. The single most important sentence on the call came in response to a question about how much of Americas growth was price:

For capital sales, it is a tremendous nice growth. But on the utilization based upon procedure sales and flow probe sales, it is actually a decline in this quarter, but compensated by price.

The CFO was unusually candid in sizing the underlying: “Underlying growth in volumes of around, I would estimate, around 10%.” — Thomas Jakobsen, CFO · 2026-10-23 That is a perfectly respectable number for a medtech niche leader. It is simply not 26%.

The imaging comeback is real — and it is a market-share story

The best-supported claim in the whole release is that imaging has reaccelerated. The imaging portfolio grew 57.9% in the quarter and 28.6% year-to-date, against 15.4% and 22.2% for flow. Management attributes this not to a rising tide but to account wins: “The current growth that we are seeing from the imaging portfolio, first of all, it is coming, I would say, primarily from winning new accounts for the imaging technology, especially in the U.S.A., but also in Europe.” — Kari Krogstad, CEO · 2026-10-23 That is a defensible reading. The company repeatedly notes it has no direct competitor for the combined flow-plus-high-frequency-ultrasound system, so share gain within its own addressable installed base is the only sensible growth engine.

Japan is the second leg of that story and it is finally visible in the numbers: a direct commercial organisation stood up last year, and the market delivered NOK 9 million of sales, up 35.7%, in the quarter — enough to debut as a fresh keyword in the company's own vocabulary. That expense line is also why salaries rose from NOK 60.3 million to NOK 67.8 million, alongside U.S. sales commissions on an exceptionally strong quarter.

The margin arc, meanwhile, is one of the more interesting small details. Gross margin improved 3 percentage points despite the company booking tariffs: NOK 5 million of expense against a NOK 2.7 million refund of the 2025 tariff that was deemed unlawful, for a net tariff expense of NOK 2.7 million in the quarter and NOK 12.5 million year-to-date. Management says U.S. price increases are designed to offset it, and the 82.1% year-to-date gross margin versus last year's 82.1% says the pass-through is working — for now. That is one policy variable this company does not control and cannot fully hedge.

The silence around vascular surgery

Here is the tension worth flagging. Over recent quarters Medistim has framed vascular surgery — specifically peripheral bypass — as its next growth frontier, anchored on the PATENT study. This quarter, vascular sales were flat, and the explanation offered was a mix artefact: customers who would have bought an Ultimate system instead bought a cardiac system with INTUI, and an Ultimate sale is recognised 50/50 across cardiac and vascular. “We are seeing the flat development on the vascular surgery side... this is reflecting a temporary product mix effect, not a shift in underlying demand.” — Kari Krogstad, CEO · 2026-10-23

Perhaps. But the remedy has slipped. Asked when INTUI would reach vascular, the CEO said: “The INTUI software for vascular and then also the Ultimate systems are in final R&D stage, but it will still take some time to get it all the way to the market. Our aim is as early as possible next year. I do not want to commit to any further than the first half of next year.” — Kari Krogstad, CEO · 2026-10-23 Until that lands, the vascular franchise is effectively running at half-throttle — and the CEO himself conceded the U.S. vascular procedure curve has shown "a little bit stagnation" tied to exactly this availability gap.

The clinical catalyst is just as long-dated as it looks. The PATENT study — a prospective, non-randomised, international multicentre trial in 450 critical-limb-ischaemia patients — now has 14 sites enrolling and five more in process, after what management calls a slow start. Enrollment completes by end-2027, one-year follow-up runs through 2028, and “analysis and publication is expected to come in 2029.” — Kari Krogstad, CEO · 2026-10-23 Anyone modelling a 2027 vascular inflection off PATENT is modelling something the company did not say. The nearer-term hope is softer: investigator case reports building awareness, the way the REQUEST study did, where surgeons changed their planned approach in as many as 25% of patients.

There is a broader market rhyme here. "Open surgery" surfaced as a global top-ranked theme this quarter, tied to the revived debate over open surgical revascularisation versus endovascular-first practice — precisely the clinical sentiment pivot Medistim's PATENT rationale leans on. The tailwind is real; the company is simply early, and the tape will not wait three years for it.

What the dividend actually says

The quiet capital-allocation signal: a first-ever quarterly dividend of NOK 2.50 per share, NOK 45.8 million in total, on top of NOK 8 per share already paid this year, under board authorisation. With equity above 71% of the balance sheet, no interest-bearing bank debt, and cash rebuilt from NOK 100 million at mid-year to NOK 175.6 million, this is a company with nothing to prove about solvency. It also implicitly concedes that the cash is not needed for M&A at scale.

The risk list is short but pointed. U.S. Medicaid cuts rolling in from January are an acknowledged, unquantified market factor — “So far, we haven't seen a lot of that. But these are market factors that are imposed on the industry and will be on Medistim as well.” — Kari Krogstad, CEO · 2026-10-23 Inventory remains deliberately high to secure critical components. And the 68% recurring revenue mix — a genuine quality marker — is precisely the line item that shrank in the U.S. this quarter.

The read: a genuinely excellent quarter that was manufactured by price, mix and software attach rather than by procedure growth, in a company whose next real leg — vascular — is now a first-half-2027 product event and a 2029 clinical one. The imaging comeback is the story to underwrite; the 26% headline is not the number to extrapolate.